Antimicrobial activity of doripenem against Gram-negative pathogens: Results from INVITA-A-DORI Brazilian Study

Brazilian Journal of Infectious Diseases

Volumn 15, Issue 6, 2011, Pages 513-520

  Gales, Ana Cristina ^a   Azevedo, Heber D ^b   Cereda, Rosângela Ferraz ^b   Girardello, Raquel ^a   Xavier, Danilo Elias ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Janssen Cilag ^*  (Brazil)

Author keywords

Brazil; Carbapenems; Gram negative bacteria

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TIGECYCLINE;

ACHROMOBACTER XYLOSOXIDANS; ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BRAZIL; BURKHOLDERIA CEPACIA; CITROBACTER; CONTROLLED STUDY; DELFTIA ACIDOVORANS; DRUG POTENCY; ENTEROBACTER; ESCHERICHIA COLI; HAFNIA; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PANTOEA; PROTEUS; PROVIDENCIA STUARTII; PSEUDOMONAS AERUGINOSA; SALMONELLA; SERRATIA;

ANTI-BACTERIAL AGENTS; BRAZIL; CARBAPENEMS; GRAM-NEGATIVE BACTERIA; HOSPITALS, PRIVATE; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 84855948099     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(11)70244-6     Document Type: Article

References (40)

1. Zhanel G.G., Wiebe R., Dilay L., et al. Comparative review of the carbapenems. Drugs 2007, 67(7):1027-1052.
2. Tsuji M., Ishii Y., Ohno A., Miyazaki S., Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 1998, 42(1):94-99.
3. Davies T.A., Shang W., Bush K., Flamm R.K. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008, 52(4):1510-1512.
4. JNJ-38174942 (Doripenem) NDA 22-171: Advisory Committee Briefing Book. Dopipenem for Injection for the Treatment of Nosocomial Pneumonia. 2008; Johnson & Johnson Pharmaceutical Research & Development. L.L.C. Meeting of Anti-Infective Drugs Advisory Committee.
5. Hanaki H, Kondo N, Inaba Y, Kuwahara K, Asada K. In vitro activity of S-4661, a new 1-beta-methyl carbapenem, against gram-positive and gram-negative bacterial isolates. 1996;36th Intersci. Conf. Antimicrob. Agents Chemother.
6. Sasaki S, Murakami K, Nishitani Y, Kuwahara S. S-4661, a new carbapenem: I. in vitro antibacterial activity. 1994; 34th Intersci. Conf. Antimicrob. Agents Chemother.
7. Cada D.J., Levien T., Mistry B., Baker D.E. Doripenem for injection. Hospital Farmacy 2008, 43(3):210-221.
8. Doribax[package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc, 2007.
9. Sader H.S., Gales A.C. Treatment of severe infections in the era of high rates of antimicrobial resistance. Braz J Infect Dis 2008, 12(Suppl 2):1-2.
10. Andrade S.S., Sader H.S., Barth A.L., Ribeiro J., Zoccoli C., Pignatari A.C., Gales A.C. Antimicrobial susceptibility patterns of gram-negative bacilli isolated in Brazilian hospitals participating in the SENTRY Program (2003-2008). Braz J Infect Dis 2008, 12(Suppl 2):3-9.
11. Horan T.C., Andrus M., Dudeck M.A. Am J Infect Control 2008, 36:309-332.
12. Clinical and Laboratory Standards Institute (CLSI). M7-A8, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition. Wayne, PA: CLSI, 2009.
13. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: nineteen informational supplement (M100-S21), Wayne, PA: CLSI, 2011.
14. Tygacil [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc, 2005.
15. Paterson D.L. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Med 2006, 119:S20-S28.
16. Canton R., Coque T.M. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006, 9:466-475.
17. Pitout J.D., Nordmann P., Laupland K.B., Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005, 56:52-59.
18. Minarini L.A., Gales A.C., Palazzo I.C., Darini A.L. Prevalence of community-occurring extended spectrum beta-lactamaseproducing Enterobacteriaceae in Brazil. Curr Microbiol 2007, 54:335-341.
19. Gales A.C., Jones R.N., Sader H.S., Fritsche T.R. Antimicrobial activity of doripenem tested against leading bacterial pathogens: Results from the Latin American Surveillance Study. Braz J Infect Dis 2008, 12(Suppl2):59-66.
20. Jones R.N., Huynh H.K., Biedenbach D.J., Fritsche T.R., Sader H.S. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004, 54:144-154.
21. Sakyo S., Tomita H., Tanimoto K., Fujimoto S., Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot 2006, 59:220-228.
22. Mushtaq S., Ge Y., Livermore D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob Agents Chemother 2004, 48:1313-1319.
23. Huynh H.K., Biedenbach D.J., Jones R.N. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis 2006, 55:241-243.
24. Redman R., File T.M. Safety of intravenous infusion of doripenem. Clin Infect Dis 2009, 49(Suppl 1):S28-S35.
25. Psathas P.A., Kuzmission A., Ikeda K., Yasuo S. Stability of doripenem in vitro inrepresentative infusion solutions and infusion bags. Clin Ther 2008, 30:2075-2087.
26. Mushtaq S., Ge Y., Livermore D.M. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004, 48:3086-3092.
27. Davies TA, Shang W, Redman R, Bush K, Flamm B. Genotyping of Gram-negative uropathogens isolated pre- and post-treatment from subjects in a doripenem clinical trial for complicated urinary tract infections, 2008. WPCCID, Taipei, Taiwan.
28. IMP-1-carrying integron In86 among Klebsiella pneumonia isolates harboring a new trimethoprim resistance gene dfr23. Diagn Microbiol Infect Dis 2009, 63:87-91.
29. Monteiro J., Santos A.F., Asensi M.D., Peirano G., Gales A.C. First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. Antimicrob Agents Chemother 2009, 53:333-334.
30. Zavascki A.P., Zoccoli C.M., Machado A.B., et al. KPC-2-producing Klebsiella pneumoniae in Brazil: a widespread threat in waiting?. Int J Infect Dis 2010, 14:539-540.
31. Van Wart S.A., Andes D.R., Ambrose P.G., Bhavnani S.M. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009, 63(4):409-414.
32. Louie A., Bied A., Fregeau C., et al. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother 2010, 54(6):2638-2645.
33. Queenan A.M., Shang W., Flamm R., Bush K. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother 2010, 54(1):565-569.
34. Gales A.C., Menezes L.C., Silbert S., Sader H.S. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. J Antimicrob Chemother 2003, 52(4):699-702.
35. Poirel L., Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006, 12(9):826-836.
36. Schimith Bier K.E., Luiz S.O., Scheffer M.C., et al. Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil. Am J Infect Control 2010, 38(4):308-314.
37. Castanheira M., Jones R.N., Livermore D.M. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 2009, 63(4):426-433.
38. Kollef M.H., Nathwani D., Merchant S., Gast C., Quintana A., Ketter N. Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators. Crit Care 2010, 14(3):R84.
39. Kongnakorn T., Mwamburi M., Merchant S., Akhras K., Caro J.J., Nathwani D. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Curr Med Res Opin 2010, 26:17-24.
40. Tóth A., Damjanova I., Puskás E., et al. Emergence of a colistinresistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis 2010, 29(7):765-769.